Phosphate homeostasis, monitoring and managment of hyperphosphatemia in patients with the Chronic Kidney diseases
This section presents material on the significance of hyperphosphatemia in patients with CKD, Dietary Therapy for Managing Hyperphosphatemia
6. Monitoring
As per KDIGO guidelines, serum phosphate, along with calcium, intact parathyroid hormone (iPTH), and 25-hydroxyvitamin D levels are estimated in all patients with an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m^2.
If the estimated glomerular filtration rate (eGFR) is between 30 to 59 mL/min/1.73 m^2, serum phosphate, and calcium should be measured every 6 to 12 months. In patients with estimated eGFR 15 to 29 mL/min/1.73 m^2, serum phosphate and calcium require assessment every three to six months
Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, Fouque D, Friedman AN, Ghaddar S, Goldstein-Fuchs DJ, Kaysen GA, Kopple JD, Teta D, Yee-Moon Wang A, Cuppari L: KDOQI clinical practice guideline for nutrition in CKD: 2020 update [published correction appears in Am J Kidney Dis S0272-6386(20): 31125–2, 2020 10.1053/j.ajkd.2020.11.004]. Am J Kidney Dis 76[Suppl 1]: S1–S107, 2020